The innovative advance could shift treatment from response to prevention, and redefine how we think about this common maternal condition.

The GABAA receptor positive allosteric modulator will be sold as Zurzuvae for PPD, which affects women after childbirth and can make it hard for new mothers to bond with their newborns.

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

Psychiatric drug developers have for years been pointing to kappa-opioid receptor (KOR) antagonists as the poster children for a new era in psychiatric medicine. These drugs are thought to ...